Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr Grunwald on Monitoring Risk Factors for Disease Progression in PV

November 20th 2024

Michael R. Grunwald, MD, discusses the importance of monitoring risk factors associated with disease progression in patients with polycythemia vera.

Venetoclax Plus 10-Day Decitabine Produces Responses in High-Risk MDS, AML

November 15th 2024

Venetoclax plus 10-day decitabine was safe and produced responses in AML and high-risk MDS.

Retrospective Data Show Pacritinib Improves TSS in Transfusion-Dependent Myelofibrosis

November 13th 2024

A retrospective study showed pacritinib improved symptoms in transfusion-dependent myelofibrosis.

Tamibarotene Plus Azacitidine Fails to Improve CR Rates in High-Risk, RARA+ MDS

November 13th 2024

SELECT-MDS-1 will be discontinued after failing to meet its primary end point of improved CR rates with tamibarotene/azacitidine in high-risk, RARA+ MDS.

Momelotinib Wins Canadian Approval for Myelofibrosis With Anemia

November 13th 2024

Health Canada has approved momelotinib for the treatment of splenomegaly and/or disease-related symptoms in myelofibrosis with moderate-to-severe anemia.

Dr DeAngelo on the Integration of JAK Inhibitors in Myelofibrosis Management

November 11th 2024

Daniel DeAngelo, MD, discusses the integration of JAK inhibitors into clinical practice for patients with myelofibrosis.

Ruxolitinib Plus Pegylated Interferon Alfa-2a Is Safe and Effective in Newly-Diagnosed PV

November 5th 2024

Ruxolitinib plus low-dose pegylated interferon alfa-2a is well tolerated and efficacious in patients with newly diagnosed polycythemia vera.

Dr DeAngelo on the Evolving Role of JAK Inhibitors in the Management of Myelofibrosis

October 30th 2024

Daniel DeAngelo, MD, PhD, discusses the evolving role of JAK inhibitors in the management of myelofibrosis and highlights remaining unmet needs for this patient population.

Dr DeAngelo on the Current Treatment Paradigm for Myelofibrosis

October 30th 2024

Daniel DeAngelo MD, PhD, discusses current treatment strategies for patients with myelofibrosis, highlighting ongoing and recently presented studies

JAK Inhibitors Remain the Gold Standard in Myelofibrosis

October 28th 2024

Daniel DeAngelo MD, PhD, discusses the incorporation of JAK inhibitors into the myelofibrosis treatment paradigm.

INCA033989 May Address Need for Disease-Modifying Therapies in Myelofibrosis

October 25th 2024

Daniel J. DeAngelo MD, PhD, discusses the potential role for INCA033989 as a disease-modifying therapy in CALR type 1–mutated myelofibrosis.

Dr Amanam on Currently Available JAK Inhibitors for Myelofibrosis

October 17th 2024

Idoroenyi Amanam, MD, discusses the JAK inhibitors he most commonly reaches for in his clinical practice when treating patients with myelofibrosis.

Dr Klisovic on a Case Discussion of Momelotinib in Myelofibrosis With Anemia

October 16th 2024

Rebecca Klisovic, MD, discusses 3 case studies about patients with myelofibrosis.

Dr Amanam on the Evolution of Myelofibrosis Management

October 11th 2024

Idoroenyi Amanam, MD, discusses potential treatment advancements in myelofibrosis and highlights the use of stem cell transplant in this disease.

Myelofibrosis Treatment Advances Rely on Past Developments to Drive Future Innovation

October 9th 2024

Idoroenyi Amanam, MD, discusses JAK inhibitor–associated AE management and considerations for the future use of stem cell transplant in myelofibrosis.

JAK Inhibitors Diversify the Field of Myelofibrosis Symptom and Spleen Management

October 8th 2024

Idoroenyi Amanam, MD, discusses characteristics that make patients with myelofibrosis most likely to derive benefit from certain JAK inhibitors.

Dr Amanam on Criteria for Selecting a JAK Inhibitor in Myelofibrosis

September 23rd 2024

Idoroenyi Amanam, MD, discusses criteria for selecting patients with myelofibrosis who may benefit from JAK inhibitors.

Tapotoclax Demonstrates Safety, Yields Anti-Leukemic Effects but No Responses in MDS Following HMAs

September 22nd 2024

Tapotoclax showed manageable safety, and it reduced bone marrow blasts and transfusion dependence in MDS after HMAs.

Dr El-Jawahri on the Benefits of Earlier Palliative Care in Hematologic Malignancies

September 20th 2024

Areej El-Jawahri, MD, discusses the potential benefits of earlier palliative care for patients with hematologic malignancies.

Dr Amanam on the Optimal Use of JAK Inhibitors in the Current Myelofibrosis Treatment Paradigm

September 19th 2024

Idoroenyi Amanam, MD, discusses the myelofibrosis treatment paradigm, highlighting patients who may derive the most benefit for JAK inhibitor treatment.